AbbVie Inc. (ABBV) Goodwill
The goodwill for AbbVie Inc. (ABBV) is $35.64 Billion with a year-over-year change of +1.96%. Goodwill is an intangible asset recorded when a company acquires another business for more than the fair value of its identifiable net assets.
ABBV Goodwill Chart
Current Goodwill
$35.64B
$35.64 Billion
Year-over-Year Change
+1.96%
vs. $34.96B prior year
Historical Data
16
Years of data available
Annual Goodwill History
| Year | Goodwill | YoY Change | % Change |
|---|---|---|---|
| 2025 | $35.64B | +$684.00M | +1.96% |
| 2024 | $34.96B | +$2.66B | +8.25% |
| 2023 | $32.29B | +$137.00M | +0.43% |
| 2022 | $32.16B | $-223.00M | -0.69% |
| 2021 | $32.38B | $-745.00M | -2.25% |
| 2020 | $33.12B | +$17.52B | +112.28% |
| 2019 | $15.60B | $-59.00M | -0.38% |
| 2018 | $15.66B | $-122.00M | -0.77% |
| 2017 | $15.79B | +$369.00M | +2.39% |
| 2016 | $15.42B | +$2.25B | +17.07% |
| 2015 | $13.17B | +$7.31B | +124.63% |
| 2014 | $5.86B | $-415.00M | -6.61% |
| 2013 | $6.28B | +$147.00M | +2.40% |
| 2012 | $6.13B | +$30.00M | +0.49% |
| 2011 | $6.10B | $-97.18M | -1.57% |
| 2010 | $6.20B | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael